1. Home
  2. EVF vs SKYE Comparison

EVF vs SKYE Comparison

Compare EVF & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$5.29

Market Cap

95.9M

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.84

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVF
SKYE
Founded
1998
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.9M
44.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EVF
SKYE
Price
$5.29
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
93.3K
338.9K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
10.68%
N/A
EPS Growth
N/A
N/A
EPS
0.94
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$0.82
52 Week High
$6.84
$5.75

Technical Indicators

Market Signals
Indicator
EVF
SKYE
Relative Strength Index (RSI) 40.02 28.69
Support Level $5.32 $0.82
Resistance Level $5.34 $1.27
Average True Range (ATR) 0.03 0.10
MACD 0.00 -0.01
Stochastic Oscillator 29.58 5.99

Price Performance

Historical Comparison
EVF
SKYE

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: